Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 in Relapsed/Refractory Classic Hodgkin's Lymphoma
NCT03155425Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jun 2017
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Classical Hodgkin Lymphoma (cHL), sponsored by Hengrui. Primary endpoint: Objective Response Rate at 36 weeks. Started Jun 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT03155425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155425.